Private Capital Advisors, Inc. Gilead Sciences, Inc. Transaction History

Private Capital Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 12, 2021	SELL	$67.69 - $73.03 $16,922 - $18,257	-250 Reduced 3.97%	6,047 $422,000
Q2 2021 Aug 06, 2021	SELL	$63.47 - $69.35 $86,319 - $94,315	-1,360 Reduced 17.76%	6,297 $434,000
Q3 2020 Nov 06, 2020	SELL	$62.1 - $78.08 $6,210 - $7,808	-100 Reduced 1.29%	7,657 $484,000
Q2 2020 Jul 28, 2020	SELL	$72.34 - $84.0 $10,851 - $12,600	-150 Reduced 1.9%	7,757 $597,000
Q1 2019 Apr 09, 2019	SELL	$62.53 - $70.05 $18,759 - $21,015	-300 Reduced 3.66%	7,907 $514,000
Q3 2018 Oct 16, 2018	SELL	$71.28 - $78.92 $302,940 - $335,410	-4,250 Reduced 34.12%	8,207 $634,000
Q3 2018 Oct 12, 2018	BUY	$71.28 - $78.92 $302,940 - $335,410	4,250 Added 51.79%	12,457 $1.01 Million
Q1 2018 Apr 18, 2018	BUY	$72.84 - $88.8 $78,812 - $96,081	1,082 Added 15.19%	8,207 $619,000
Q4 2017 Jan 12, 2018	SELL	$71.15 - $83.52 $379,371 - $445,328	-5,332 Reduced 42.8%	7,125 $510,000
Q3 2017 Oct 18, 2017	BUY	$72.11 - $85.47 $898,274 - $1.06 Million	12,457	12,457 $1.01 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Private Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Private Capital Advisors, Inc. with notifications on news.